arrow
返回
Y

Yoshihiko Tomita

Niigata University

56H指数
472论文数
2.6W被引数
收录论文 124
发表时间
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果
err2025-10-17
err0
errOAAI
errM.D. Galsky; J.E. Gschwend; M.I. Milowsky; M. Schenker; B.P. Valderrama; Y. Tomita; A. Bamias; T. Lebret; S.F. Shariat; S.H. Park; M. Agerbaek; G. Jha; F. Stenner; D. Ye; F. Giudici; J. Connors; S. Gupta; A. Chhibber; J. Zhang; D.F. Bajorin; J.A. Witjes
err分享
err收藏
GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab全基因组关联研究(GWAS)鉴定出与接受纳武利尤单抗治疗的晚期肾细胞癌患者严重不良事件及疗效相关的单核苷酸多态性(SNP)。
err2025-09-24
err0
errOAAI
errTokiyoshi Tanegashima; Masaki Shiota; Shusuke Akamatsu; Hideaki Miyake; Masayuki Takahashi; Mototsugu Oya; Norihiko Tsuchiya; Naoya Masumori; Hideyasu Matsuyama; Wataru Obara; Nobuo Shinohara; Kiyohide Fujimoto; Masahiro Nozawa; Kojiro Ohba; Chikara Ohyama; Katsuyoshi Hashine; Tomomi Kamba; Koji Mita; Momokazu Gotoh; Shuichi Tatarano; Masato Fujisawa; Yoshihiko Tomita; Shoichiro Mukai; Keiichi Ito; Shoji Tokunaga; Masatoshi Eto; SNiP-RCC investigators
err分享
err收藏
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial来自随机III期CheckMate 9ER试验的尼鲁单抗联合卡博赞替尼治疗晚期肾细胞癌的最终分析
err2025-09-23
err0
errOAAI
errR.J. Motzer; B. Escudier; M. Burotto; T. Powles; A.B. Apolo; M.T. Bourlon; A.Y. Shah; C. Porta; C. Suárez; C.H. Barrios; M. Richardet; H. Gurney; E.R. Kessler; Y. Tomita; J. Bedke; C. Scheffold; M. Askelson; J. Panzica; J. Zhang; M. van Kooten Losio; T.K. Choueiri
err分享
err收藏
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial辅助性纳武利尤单抗在肌肉浸润性尿路上皮癌中的应用:随机III期CheckMate 274试验的探索性生物标志物分析
err2025-08-07
err0
PREAI
errMatthew D. Galsky; Dean F. Bajorin; Yoshihiko Tomita; Dingwei Ye; Mads Agerbaek; Deborah Enting; Avivit Peer; Matthew Milowsky; Ko Kobayashi; Marc-Oliver Grimm; Frank Stenner; Justin M. David; Jun Li; Scott D. Chasalow; Federico Nasroulah; Abraham Apfel; Keziban Ünsal-Kaçmaz; Andrea Necchi
err分享
err收藏
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 TrialCheckMate 901试验中,仅淋巴结转移性尿路上皮癌患者接受纳武利尤单抗联合吉西他滨-顺铂治疗与单独吉西他滨-顺铂治疗的特征分析
err2025-05-20
err0
errOAAI
errMatthew D. Galsky; Michiel S. van der Heijden; Thomas Powles; Melanie Claps; Mauricio Burotto; Michael Schenker; Juan Pablo Sade; Aristotelis Bamias; Philippe Beuzeboc; Jens Bedke; Jan Oldenburg; Yüksel Ürün; Dingwei Ye; Begoña P. Valderrama; Yoshihiko Tomita; Ruiyun Jiang; Jeiry Filian; Lily Wang; Maximiliano van Kooten Losio; Guru Sonpavde
err分享
err收藏
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsAvelumab一线维持治疗晚期尿路上皮癌:JAVELIN Bladder 100试验中老年患者长期结局
err2025-04-01
err0
PREAI
errGupta, S.; Duran, M. A. Climent; Sridhar, S. S.; Powles, T.; Bellmunt, J.; Park, S. H.; Gurney, H.; Tsuchiya, N.; Petrylak, D. P.; Tomita, Y.; di Pietro, A.; Manitz, J.; Tyroller, K.; Hoffman, J.; Jacob, N.; Grivas, P.
err分享
err收藏
Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trialavelumab联合达沙替尼与舒尼替尼作为晚期肾细胞癌患者的一线治疗:JAVELIN Renal 101 III期试验的最终分析
err2024-12-01
err3
PREAI
errChoueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; Eertwegh, A. J. M. van den; Negrier, S.; Gurney, H.; Albiges, L.; Berger, R.; Haanen, J. B. A. G.; Juarez, V. Oyervides; Rini, B. I.; Larkin, J.; Nole, F.; Schmidinger, M.; Atkins, M. B.; Tomita, Y.; Ellers-Lenz, B.; Hoffman, J.; Sandner, R.; Wang, J.; di Pietro, A.; Motzer, R. J.
err分享
err收藏
Concordance Between Pharmaceuticals and Medical Devices Agency Review and Ministry of Health, Labour and Welfare Decision Among New Drug Applications in Japan
err2024-11-08
err0
errOAAI
errMiyazawa, Makoto; Tanaka, Mototsugu; Tanaka, Yusuke; Terashima, Ryohei; Ezura, Mio; Miyazawa, Haruna; Ikuma, Mutsuhiro; Tomita, Yoshihiko
err分享
err收藏
Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution
err2024-11-02
err0
errOAAI
errIshizaki, Fumio; Taguchi, Takahiro; Murata, Masaki; Hoshino, Sayaka; Toba, Tomotaka; Takeda, Keisuke; Tasaki, Masayuki; Yamana, Kazutoshi; Kasahara, Takashi; Hoshii, Tatsuhiko; Obara, Kenji; Saito, Kazuhide; Tomita, Yoshihiko
err分享
err收藏
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialNivolumab联合ipilimumab与舒尼替尼用于晚期肾细胞癌的一线治疗: CheckMate 214 III期试验的疗效和安全性的8年随访结果
err2024-11-01
err0
errOAAI
errTannir, N. M.; Albiges, L.; Mcdermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthelemy, P.; Plimack, E. R.; Portat, C.; George, S.; Donskov, F.; Atkins, M. B.; Gurney, H.; Kollmannsberger, C. K.; Grimm, M. -o.; Barrios, C.; Tomita, Y.; Castellano, D.; Gruenwald, V.; Rini, B. I.; Jiang, R.; Desilva, H.; Fedorov, V.; Lee, C. -w.; Motzer, R. J.
err分享
err收藏
On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy
err2024-06-01
err3
PREAI
errSaal, Jonas; Gruenwald, Viktor; Bald, Tobias; Ritter, Manuel; Brossart, Peter; Tomita, Yoshihiko; Hartmann, Arndt; Holzel, Michael; Eckstein, Markus; Kluemper, Niklas
err分享
err收藏
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study
err2024-05-17
err0
errOAAI
errTanegashima, Tokiyoshi; Shiota, Masaki; Fujiyama, Nobuhiro; Narita, Shintaro; Habuchi, Tomonori; Fukuchi, Genshiro; Takamatsu, Dai; Oda, Yoshinao; Miyake, Hideaki; Takahashi, Masayuki; Oya, Mototsugu; Tsuchiya, Norihiko; Masumori, Naoya; Matsuyama, Hideyasu; Obara, Wataru; Shinohara, Nobuo; Fujimoto, Kiyohide; Nozawa, Masahiro; Ohba, Kojiro; Ohyama, Chikara; Hashine, Katsuyoshi; Akamatsu, Shusuke; Kamba, Tomomi; Mita, Koji; Gotoh, Momokazu; Tatarano, Shuichi; Fujisawa, Masato; Tomita, Yoshihiko; Mukai, Shoichiro; Ito, Keiichi; Tokunaga, Shoji; Eto, Masatoshi
err分享
err收藏
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialNivolumab联合卡博替尼与舒尼替尼一线治疗晚期肾细胞癌: III期随机CheckMate 9ER试验的延长随访
err2024-05-01
err18
errOAAI
errPowles, T.; Burotto, M.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; Gurney, H.; Kessler, E. R.; Tomita, Y.; Bedke, J.; George, S.; Scheffold, C.; Wang, P.; Fedorov, V.; Motzer, R. J.; Choueiri, T. K.
err分享
err收藏
Postmarket safety communications on drugs approved in Japan: A 25-year analysis
err2024-04-23
err0
errOAAI
errTanaka, Yusuke; Tanaka, Mototsugu; Miyazawa, Haruna; Terashima, Ryohei; Miyazawa, Makoto; Ikuma, Mutsuhiro; Tomita, Yoshihiko
err分享
err收藏
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score (vol 83, pg 432, 2024)
err2024-03-01
err1
errOAAI
errGalsky, Matthew D.; Bajorin, Dean F.; Witjes, Johannes Alfred; Gschwend, Juergen E.; Tomita, Yoshihiko; Nasroulah, Federico; Li, Jun; Collette, Sandra; Valderrama, Begona P.; Grimm, Marc-Oliver; Appleman, Leonard; Gravis, Gwenaelle; Necchi, Andrea; Ye, Dingwei; Stenner, Frank; Wind-Rotolo, Megan; Zhang, Joshua; uensal-Kacmaz, Keziban
err分享
err收藏
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
err2023-12-01
err6
errOAAI
errTomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Oya, M.; Albiges, L.; Aizawa, M.; Umeyama, Y.; Wang, J.; di Pietro, A.; Schmidinger, M.
err分享
err收藏
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
err2023-11-09
err148
PREAI
errvan der Heijden, M. S.; Sonpavde, G.; Powles, T.; Necchi, A.; Burotto, M.; Schenker, M.; Sade, J. P.; Bamias, A.; Beuzeboc, P.; Bedke, J.; Oldenburg, J.; Chatta, G.; Urun, Y.; Ye, D.; He, Z.; Valderrama, B. P.; Ku, J. H.; Tomita, Y.; Filian, J.; Wang, L.; Purcea, D.; Patel, M. Y.; Nasroulah, F.; Galsky, M. D.
err分享
err收藏
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
err2023-09-02
err1
errOAAI
errMotzer, Robert J.; Russo, Paul; Gruenwald, Viktor; Tomita, Yoshihiko; Zurawski, Bogdan; Parikh, Omi; Buti, Sebastiano; Barthelemy, Philippe; Goh, Jeffrey C.; Ye, Dingwei; Lingua, Alejo; Lattouf, Jean-Baptiste; Albiges, Laurence; George, Saby; Shuch, Brian; Sosman, Jeffrey; Staehler, Michael; Vazquez Estevez, Sergio; Simsek, Burcin; Spiridigliozzi, Julia; Chudnovsky, Aleksander; Bex, Axel
err分享
err收藏
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
err2023-05-01
err14
errOAAI
errGalsky, Matthew D.; Bajorin, Dean F.; Witjes, Johannes Alfred; Gschwend, Juergen E.; Tomita, Yoshihiko; Nasroulah, Federico; Li, Jun; Collette, Sandra; Valderrama, Begona P.; Grimm, Marc-Oliver; Appleman, Leonard; Gravis, Gwenaelle; Necchi, Andrea; Ye, Dingwei; Stenner, Frank; Wind-Rotolo, Megan; Zhang, Joshua; Unsal-Kacmaz, Keziban
err分享
err收藏